Investing.com -- Propanc Biopharma Inc (NASDAQ:PPCB) stock rose 5.4% on Monday after the biopharmaceutical company announced it has submitted a request for a foreign filing license from Spain for two provisional patents.
The patents detail new methods to treat resistant cancer and fibrosis, and will be filed with IP Australia under the company’s wholly owned subsidiary, Propanc Pty Ltd. These discoveries emerged from Propanc’s Joint Research and Drug Discovery program with Spanish universities.
The first patent covers methods for treating cancers that have developed resistance to chemotherapy and radiotherapy, while the second relates to compositions and methods for treating fibrosis, particularly organ fibrosis. The fibrosis patent represents the first in Propanc’s portfolio to describe the use of its lead product candidate, PRP, for chronic diseases beyond cancer.
"The submission of these two patents represents a significant turning point for Propanc and the commercial potential of PRP for treating chronic diseases such as cancer and fibrosis," said James Nathanielsz, Propanc’s Chief Executive Officer.
The company plans to conduct a Phase 1b, First-In-Human study in 2026 to define the target therapeutic dose of PRP, which would enable exploration of this proenzyme therapy across multiple disease conditions in Phase 2 proof-of-concept studies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
